No connection

Search Results

AYTU vs MLSS

AYTU
Aytu BioPharma, Inc.
NEUTRAL
Price
$2.70
Market Cap
$27.5M
Sector
Healthcare
AI Confidence
65%
MLSS
Milestone Scientific Inc.
BEARISH
Price
$0.31
Market Cap
$27.4M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
AYTU
--
MLSS
--
Forward P/E
AYTU
15.88
MLSS
-7.75
P/B Ratio
AYTU
1.15
MLSS
8.86
P/S Ratio
AYTU
0.43
MLSS
3.05
EV/EBITDA
AYTU
3.86
MLSS
-4.42

Profitability

Gross Margin
AYTU
67.56%
MLSS
71.4%
Operating Margin
AYTU
-10.83%
MLSS
-52.46%
Profit Margin
AYTU
-20.52%
MLSS
-63.77%
ROE
AYTU
-50.23%
MLSS
-132.38%
ROA
AYTU
0.61%
MLSS
-40.45%

Growth

Revenue Growth
AYTU
-16.2%
MLSS
2.2%
Earnings Growth
AYTU
--
MLSS
--

Financial Health

Debt/Equity
AYTU
1.23
MLSS
0.36
Current Ratio
AYTU
1.23
MLSS
1.81
Quick Ratio
AYTU
1.0
MLSS
0.44

Dividends

Dividend Yield
AYTU
--
MLSS
--
Payout Ratio
AYTU
0.0%
MLSS
0.0%

AI Verdict

AYTU NEUTRAL

The Advanced Deterministic Scorecard shows a weak Piotroski F-Score of 4/9, indicating borderline financial health, and the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite unprofitability (ROE: -50.23%, Profit Margin: -20.52%) and declining revenue (YoY -16.20%), the stock has seen strong short-term price momentum (+61.7% 1Y) and a bullish analyst recommendation (strong_buy) with a high target price of $9.33. High gross margins (67.56%) and improving quarterly earnings surprises (avg +98.68% last 4 quarters) suggest operational progress, but weak cash visibility, leverage (Debt/Equity: 1.23), and inconsistent earnings history remain concerns. The stock trades at a forward P/E of 15.88, below sector average, potentially reflecting skepticism around sustainability.

Strengths
High gross margin (67.56%) indicates strong pricing power or low production costs
Recent earnings surprises significantly positive (avg +98.68% last 4 quarters)
Analyst consensus is strong_buy with a high target price ($9.33) implying 245% upside
Risks
Piotroski F-Score of 4/9 indicates weak financial health and poor profitability
Profitability remains negative (Profit Margin: -20.52%, ROE: -50.23%)
Revenue declining YoY (-16.20%) and limited financial transparency (missing cash/debt data)
MLSS BEARISH

MLSS exhibits severe financial distress, highlighted by a Piotroski F-Score of 1/9, indicating critical weakness across nearly all fundamental health dimensions. The company suffers from chronic unprofitability with a profit margin of -63.77% and an ROE of -132.38%, while revenue growth has stagnated at a negligible 2.20% YoY. Despite a low debt-to-equity ratio, the poor quick ratio (0.44) and consistent earnings misses over 25 quarters suggest a failing business model. The stock is technically bearish with a 5-year price decline of 87.7%, making it a high-risk speculative asset with no fundamental floor.

Strengths
Strong gross margin of 71.40% suggesting a viable product core
Low Debt/Equity ratio (0.36) indicating minimal long-term leverage
Current ratio of 1.81 provides a temporary liquidity buffer
Risks
Critical financial health (Piotroski F-Score 1/9)
Chronic net losses with negative profit and operating margins
Stagnant revenue growth (2.20%) failing to scale the business

Compare Another Pair

AYTU vs MLSS: Head-to-Head Comparison

This page compares Aytu BioPharma, Inc. (AYTU) and Milestone Scientific Inc. (MLSS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile